Measurement of cyclooxygenase isozyme inhibition in humans: Exploring the clinical relevance of biochemical selectivity

Clinical and Experimental Rheumatology

Volumn 19, Issue 6 SUPPL. 25, 2001, Pages

  Patrono, C ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Coxibs; Monocyte COX 2; Platelet COX 1; Whole blood assay

Indexed keywords

6 METHOXY 2 NAPHTHYLACETIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; INDOMETACIN; ISOENZYME; MELOXICAM; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIROXICAM; PROSTAGLANDIN SYNTHASE; ROFECOXIB;

ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; DIGESTIVE SYSTEM ULCER; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; ENZYME INHIBITION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HUMAN TISSUE; IC 50; PRIORITY JOURNAL; PROBABILITY; RHEUMATOID ARTHRITIS; RISK FACTOR; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD PLATELETS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; MONOCYTES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; STOMACH ULCER; SUBSTRATE SPECIFICITY;

EID: 0034782128     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. The anti-inflammatory properties and safety of coxibs, selective inhibitors of cyclooxygenase-2
2. 4-(5-methyl-3-phenylisoxazol-4-yl)-benzene-sulfonamide, valdecoxib: A potent selective inhibitor of COX-2
3. Etoricoxib (MK-0663): Preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2
4. Cyclooxygenase-selective inhibition of prostanoid formation: Transducing biochemical selectivity into clinical readouts
5. Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators
6. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects
7. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases
8. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis The CLASS Study: A randomized controlled trial
9. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
10. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects
11. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs
12. Rofecoxib (Vioxx, MK-0966; 4-(4′-methyl-sulfonylphenyl)-3-phenyl-2-(5H)-furanone): A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles
13. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis
14. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs
15. Biochemical selectivity of rofecoxib in rheumatoid arthritis
16. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
17. Prostaglandin H synthase 2 variant in African Americans may reduce the risk for colorectal adenomas
18. Clinical pharmacokinetics and pharmacodynamics of celecoxib: A selective cyclo-oxygenase-2 inhibitor
19. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs
20. The risk of upper gastrointestinal complications among users of acetaminophen and other non-steroidal anti-inflammatory drugs
21. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial
22. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind comparison
23. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor
24. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
25. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen
26. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial
27. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
28. Cyclooxygenase-selective inhibition of prostanoid formation: Transducing biochemical selectivity into clinical readouts